Today: 6 July 2026
UiPath Stock Rises Near $10 as Investors Weigh AI Automation Growth Against Valuation Risk
16 June 2026
1 min read

UiPath Rises as AI Seen Driving Growth, Risk Remains

New York, June 16, 2026, 05:04 ET

  • UiPath ended Monday at $10.79, up 2.27% for the session. Shares are still down steeply for 2026.
  • The company hasn’t put out a new statement. Traders kept to tracking valuation, AI demand and ARR growth.
  • Traders are now looking ahead to fiscal Q2 earnings. Market-data calendars put the release on Sept. 8.

UiPath, Inc. (NYSE: PATH) shares rose 2.27% to $10.79 on Monday, FinanceCharts said. The stock is off its lows but remains down 34.17% for the year. PATH has ranged from $9.20 to $19.84 over the last 52 weeks. The company’s investor news page shows no updates since the June 4 post about One NZ. Traders are looking for other catalysts now.

UiPath shares climbed, but investors are still asking if enterprise AI will fuel continued recurring revenue gains. The company posted fiscal 2027 first-quarter revenue of $418 million, up 17%. Annual recurring revenue was $1.901 billion, a 12% increase. CEO Daniel Dines said it was “a strong start to the fiscal year.” UiPath also reported its first-ever GAAP profit for a Q1. UiPath, Inc.

Some bulls point to the basics. UiPath is profitable, has a strong cash position, and just raised its full-year fiscal 2027 outlook after reporting Q1 results. The company now sees revenue between $1.776 billion and $1.781 billion, projects ARR of $2.058 billion to $2.063 billion, and expects non-GAAP operating income to land near $430 million. These non-GAAP figures leave out things like stock-based comp, meant to show what bulls call the underlying business, but they don’t replace GAAP numbers. Valuation is another thing bulls track. UiPath’s EV-to-sales sits at 2.58, FinanceCharts shows, below its three-year average of 3.86. That metric factors in cash and debt, putting enterprise value up against revenue from the last year.

Wall Street stays cautious. Out of 17 analysts tracked by MarketBeat, 14 call the stock a hold, with two buys and one sell. The consensus is “Hold.” The average price target stands at $13.87, a little over Monday’s close. Morgan Stanley’s Sanjit Singh dropped his price target to $15 from $17, keeping an Equal Weight. Singh said Q1 was fine, but ARR is slow to move, calling it a “show-me” story. MarketBeat

PATH isn’t trading cheap, so buyers face some risk. The stock has not been moving like a leading software momentum play, though bulls may like the fundamentals. Execution risk seems built in. UiPath still needs to turn early AI pilots into larger ARR-generating deals. The fiscal Q2 update is the next big event. Markets Insider lists the annual meeting on June 25 and Q2 fiscal 2027 earnings for Sept. 8. The earnings report will likely drive the biggest move.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Veradermics (NYSE: VRDM) Jumps 656% Since IPO as Obesity Drug Momentum Lifts Cash-Pay Biotech
    July 6, 2026, 11:45 AM EDT. Veradermics stock is up 656% since its February listing on the NYSE, well ahead of the XBI biotech index, which rose 24%. The company sells an oral extended-release minoxidil for male and female pattern hair loss. CEO Reid Waldman said part of the move is due to strong demand for obesity drugs from Eli Lilly and Novo Nordisk, with those sales helping validate consumer-focused, cash-pay models. Lilly looked at a potential stake at the IPO price, showing big pharma interest. Veradermics is betting on direct-to-consumer sales and linking hair loss and weight management markets to find new growth paths.
Grab shares jump as GRAB investors focus on Superbank move after Nasdaq climb
Previous Story

Grab shares jump as GRAB investors focus on Superbank move after Nasdaq climb

SL Science Holding pops at Nasdaq open, SPAC risks linger
Next Story

SL Science Holding pops at Nasdaq open, SPAC risks linger

Go toTop